National Cancer Institute
Found 1005 results for your search:
Total relevant funding to Chemotherapy for this search:
$317,746,569
Fiscal Year FY 2017
Research Topic [Chemotherapy]
Modify this Search New Search
Close

Modify Search Criteria

Some search criteria may be modified to refine your current search.

Select criteria to modify:

Add or remove search options:

Select criteria above to see additional search options

Cancel
Showing 1 - 50 of 1005 results
Clipboard
Project Title Sorted ascending Project Number Funded Amount
Relevant Funding
Principal
Investigator
Institution
1
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients 5R21CA205636-02 $202,275 $101,138 CHEN, GRACE UNIVERSITY OF MICHIGAN
2
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities 1R01CA216290-01 $338,903 $338,903 PYTER, LEAH OHIO STATE UNIVERSITY
3
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblastoma 5R01CA190121-05 $362,088 $119,489 VERHAAK, ROELAND JACKSON LABORATORY
4
(PQ 9) Dysregulation of epidermal MMP-13 as cause of paclitaxel-induced peripheral neuropathy 1R01CA215973-01 $443,022 $443,022 RIEGER, SANDRA MOUNT DESERT ISLAND BIOLOGICAL LAB
5
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy 1R21CA215985-01 $198,000 $198,000 CHANG, KAREN UNIVERSITY OF SOUTHERN CALIFORNIA
6
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer. 5R01CA206025-02 $637,172 $637,172 GUISE, THERESA INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
7
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy 5R21CA205644-02 $202,439 $202,439 WHITESIDE, THERESA UNIVERSITY OF PITTSBURGH AT PITTSBURGH
8
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer 1R01CA219880-01 $697,539 $348,770 PALUCKA, ANNA KAROLINA JACKSON LABORATORY
9
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa 1R21CA217137-01 $209,093 $209,093 EL-MALLAWANY, NADER BAYLOR COLLEGE OF MEDICINE
10
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity 5R01CA205967-02 $386,588 $386,588 LETAI, ANTHONY DANA-FARBER CANCER INST
11
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity 5R01CA205101-02 $388,402 $388,402 SKALA, MELISSA MORGRIDGE INSTITUTE FOR RESEARCH, INC.
12
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae 5R01CA208634-02 $560,277 $560,277 JURECIC, ROLAND UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
13
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle 5R21CA205437-03 $168,236 $168,236 WANING, DAVID PENNSYLVANIA STATE UNIV HERSHEY MED CTR
14
(PQ9) Prevention of Bleomycin-induced Pulmonary Toxicity by Dichloroacetate (DCA) 5R21CA208746-02 $173,586 $173,586 KIM, JUNG-WHAN UNIVERSITY OF TEXAS DALLAS
15
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy 5R01CA205255-02 $577,463 $577,463 SEGAL, ROSALIND DANA-FARBER CANCER INST
16
(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment 1R01CA217934-01 $455,149 $455,149 ST CLAIR, DARET UNIVERSITY OF KENTUCKY
17
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy 1R01CA205166-01A1 $536,312 $536,312 KELLEY, MARK INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
18
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL 5R01CA184922-04 $553,684 $276,842 WU, CATHERINE DANA-FARBER CANCER INST
19
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers 5R01CA184968-04 $509,161 $254,581 SIKIC, BRANIMIR STANFORD UNIVERSITY
20
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies 5R01CA185372-04 $321,625 $321,625 RICHARDS, KRISTY CORNELL UNIVERSITY
21
(PQD5) Avatar-directed Treatment for Ovarian Cancer 5R01CA184502-04 $714,297 $714,297 WEROHA, SARAVUT MAYO CLINIC ROCHESTER
22
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling 5R01CA185353-04 $405,890 $405,890 KIM, WILLIAM UNIV OF NORTH CAROLINA CHAPEL HILL
23
0021.0001 CG 425 METAVIVOR 261200800001E $319,219,481 $1,992 UNKNOWN, UNKNOWN LEIDOS BIOMEDICAL RESEARCH, INC.
24
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research 5U54CA156734-07 $1,700,705 $102,042 COLON-CARMONA, ADAN UNIVERSITY OF MASSACHUSETTS BOSTON
25
2/2 NCCU-LCCC Partnership in Cancer Research 5U54CA156733-08 $919,471 $73,558 EARP, HENRY UNIV OF NORTH CAROLINA CHAPEL HILL
26
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research 5U54CA156732-07 $1,834,682 $256,855 VISWANATH, KASISOMAYAJULA DANA-FARBER CANCER INST
27
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership 5U54CA118623-12 $407,680 $12,230 TROY, ROBERTA TUSKEGEE UNIVERSITY
28
2D and 3D Contrast-enhanced Ultrasound Evaluation of HCC Chemoembolization 5R01CA194307-02 $548,690 $548,690 EISENBREY, JOHN THOMAS JEFFERSON UNIVERSITY
29
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis 5R01CA195443-02 $252,908 $126,454 WILLMANN, JUERGEN STANFORD UNIVERSITY
30
A functional genomics approach to determine the mechanism of cellular response to new anti-cancer 4R00CA204602-02 $249,000 $249,000 GILBERT, LUKE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
31
A network platform to connect drug response and prognosis phenotypes for cancers 5R01CA196631-02 $395,911 $395,911 LI, HU MAYO CLINIC ROCHESTER
32
A novel combinatorial approach for treating HPV-associated malignancies 1R43CA221479-01 $191,115 $191,115 FILIPPOVA, MARIA ISPIN, INC.
33
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER 5F30CA189435-04 $49,044 $49,044 SOM, AVIK WASHINGTON UNIVERSITY
34
A novel miR-198 replacement therapy for pancreatic cancer 5R01CA183984-03 $473,915 $236,958 YAO, QIZHI BAYLOR COLLEGE OF MEDICINE
35
A Novel PET Probe for Use in Cancer Diagnostics 2R44CA216539-02 $997,667 $329,230 MOORE, MELISSA SOFIE BIOSCIENCES, INC.
36
A p53/NFkB-mediated metabolic mechanism for chemotherapy protection 5R01CA183074-04 $335,113 $335,113 YUAN, ZHI-MIN HARVARD SCHOOL OF PUBLIC HEALTH
37
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma 1R44CA217591-01 $621,000 $621,000 KAHN, STUART SYNTRIX BIOSYSTEMS, INC.
38
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome 1R44CA213519-01 $999,914 $999,914 ISAACMAN, STEVEN NANOMETICS, LLC
39
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy 5R44CA206606-02 $1,004,186 $1,004,186 WINRAM, SCOTT CYNVEC, LLC
40
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas 5R01CA198076-03 $1 $1 PORTNOW, JANA BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
41
A Phase I trial combining IV fenretinide and IV safingol to target overproduction 4R44CA183316-02 $648,029 $648,029 SIMPSON, WILLIAM CERRX, INC.
42
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning 5R01CA199137-03 $392,439 $129,505 AVIS, NANCY WAKE FOREST UNIVERSITY HEALTH SCIENCES
43
A Question Prompt List to Promote Communication in Genomic Medicine 5R21CA201827-02 $172,029 $86,015 O'NEILL, SUZANNE GEORGETOWN UNIVERSITY
44
A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherence 1R01CA207753-01A1 $675,231 $675,231 SANFT, TARA YALE UNIVERSITY
45
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States 1U01CA217885-01 $1,011,983 $1,011,983 TAMAYO, PABLO UNIVERSITY OF CALIFORNIA SAN DIEGO
46
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy 5R01CA169519-05 $311,250 $311,250 SALVEMINI, DANIELA SAINT LOUIS UNIVERSITY
47
Aberrant signaling in acute myeloid leukemia 3R01CA204396-02S1 $232,133 $232,133 KENTSIS, ALEX SLOAN-KETTERING INST CAN RESEARCH
48
Aberrant signaling in acute myeloid leukemia 5R01CA204396-02 $459,674 $459,674 KENTSIS, ALEX SLOAN-KETTERING INST CAN RESEARCH
49
Abramson Cancer Center Support Grant 3P30CA016520-41S1 $125,000 $7,500 DANG, CHI UNIVERSITY OF PENNSYLVANIA
50
Abramson Cancer Center Support Grant 3P30CA016520-41S2 $62,491 $3,749 VONDERHEIDE, ROBERT UNIVERSITY OF PENNSYLVANIA
Total relevant funding to Chemotherapy for this search: $317,746,569
Showing 1 - 50 of 1005 results
Go to top